AI Article Synopsis
- A case study reported on a 7-year-old male with severe health issues, who developed fungal sepsis due to a Candida glabrata infection following surgery for bowel herniation.
- The treatment involved three antifungal approaches, including high-dose liposomal amphotericin, caspofungin, and the novel monoclonal antibody Mycograb, administered at 1 mg/kg twice daily for five days.
- Results showed a significant reduction in C-reactive protein levels and overall improvement in the patient's physiological parameters, indicating Mycograb was effective but further research is necessary for pediatric application.
Article Abstract
Objective: To report a case of fungal sepsis treated prospectively with liposomal amphotericin, caspofungin, and a novel monoclonal antibody specific for candidal heat shock protein 90 (Mycograb, Neutec Pharma, Manchester, UK).
Design: Case report.
Setting: Pediatric intensive care unit in a tertiary care children's hospital.
Patient: A 7-yr-old male with a history of global developmental delay, epilepsy, and gastroesophageal reflux, who presented to the emergency department with a transdiaphragmatic herniation of bowel and subsequent Candida glabrata infection.
Interventions: Efungumab 1 mg/kg twice daily for 5 days.
Measurements And Main Results: C-reactive protein fell from 225 mg/L to 99 mg/L, and physiological monitoring parameters improved when Mycograb was used in conjunction with high-dose antifungals.
Conclusions: Mycograb therapy was well tolerated, but further experience with this therapy in children is needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PCC.0b013e31817286e8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!